All Articles

Thirty years ago, a US human rights report on a mining giant disappeared. A new investigation asks why, exposing a pattern of secrecy and human cost.

A unique 'double feature' in Rocky Mount pairs local artists with a prison art program, revealing art's power for community building and rehabilitation.

As employees flock to prediction markets, a new insider trading risk emerges. A new tech alliance aims to give firms the visibility they've been missing.

Painterland Sisters just declared National Skyr Yogurt Day. It's not just a PR stunt; it's a masterclass in modern brand-building and a bet on the future of dairy.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

Hillman Group breaks ground on a massive facility at a dead mall site, centralizing operations in a bold strategic play for efficiency and future growth.

As Terry Duffy moves to Executive Chairman, Lynne Fitzpatrick prepares to lead CME. This isn't just succession; it's a calculated move for a new digital era.

As ad tech firm Swivel staffs up with industry veterans, it's not just building a company—it's signaling the ad industry's shift from AI hype to execution.

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

A CAD$40M deal with NorthStar isn't just a contract; it's a strategic pivot, leveraging commercial innovation to gain a sovereign edge in a contested space.

XCharge's new C7 charger boasts record power, but its real test lies in winning public trust. A deep dive into the tech, strategy, and partnerships redefining speed.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

Glass House Brands follows a new playbook, splitting its business to chase a NYSE listing. Is this the key that unlocks institutional capital for the entire sector?

A new mid-year outlook reveals how geopolitical turmoil, the AI boom, and a renewed focus on sovereignty are reshaping investment strategies for a volatile H2 2026.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

A new low-risk trial program for hybrid vehicles reveals China's pragmatic strategy to win over markets where pure EVs can't yet compete.

Three of Europe's largest steelmakers warn the EU's climate policy could gut manufacturing. Is this a genuine crisis or a last-ditch bid to delay the inevitable?

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

For the second year, Kuveyt Türk's academy wins a top global award. We look inside the operational innovation driving its success: an AI-powered talent engine.